Le Lézard
Subject: ATY

Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX) - April 9, 2024 Deadline to Join - Contact Levi & Korsinsky


NEW YORK, March 20, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amylyx investors who were adversely affected by alleged securities fraud between November 11, 2022 and November 8, 2023. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=71694&wire=4

AMLX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) defendants had overstated commercial prospects RELYVRIO, a dual UPRBax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the U.S.; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, defendants had also overstated RELYVRIO's prescription rate; (v) defendants attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO's prescription data; and (vi) as a result, defendants' public statements were materially false and misleading at all relevant times.

WHAT'S NEXT? If you suffered a loss in Amylyx during the relevant time frame, you have until April 9, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP



News published on and distributed by: